

# capture seq


Compelling proof-of-concept clinical data. A world first in **isolating pure tumor-derived DNA** from a liquid biopsy

Capture-Seq™ used a liquid biopsy to detect cancer across 6 tumor types, including hard to detect early-stage cancers

## Development (training)



### Cohort

- 10 Lung
- 10 Colorectal
- 10 Prostate
- 10 Breast
- 5 Liver
- 4 Bile duct
- 21 Controls



## Blinded independent validation

### Cohort

-  31 Lung Cancer
-  28 Colorectal Cancer
- 22 Healthy controls

Cancer stage	Detection rate
I	<b>100%</b> (11/11)
II	<b>100%</b> (12/12)
III	<b>100%</b> (11/11)
IV	<b>100%</b> (18/18)

All stages Sensitivity= 100% (49/49)

Controls Specificity= 100% (21/21)

Cancer stage	Detection rate
I	<b>94%</b> (17/18)
II	<b>96%</b> (26/27)
III	<b>100%</b> (2/2)
IV	<b>94%</b> (10/11)
Unknown	<b>0%</b> (0/1)

All stages Sensitivity= 93% (55/59)

Healthy Specificity= 95% (21/22)



## Potential to revolutionize cancer detection

- World first isolation of transcription factor-DNA from blood
- World first preparation of pure tumor-derived DNA sequence data sets
- A novel class of thousands of new biomarkers
- Compelling proof-of-concept clinical data

Early detection



Find cancer early



Improve outcomes

Finding MRD after treatment



Adjust treatment



Improve outcomes

Treatment monitoring



Assess treatment response



Adjust treatment



Improve outcomes